Cord blood treatment to keep leukemia in remission
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether giving a cord blood stem cell infusion after standard chemotherapy helps keep older adults with AML in remission longer. Cord blood cells may help rebuild your immune system and fight any remaining leukemia cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 80 years old.
- You have acute myeloid leukemia (AML) with certain genetic changes (but not APL or TP53 mutations).
- You have achieved remission after your first treatment or after one cycle of consolidation.
- Your liver, kidney, and heart function are within safe limits.
- You are able to perform daily activities (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
This trial tests a new way to do cord blood transplants for people with high-risk leukemia. It adds extra white blood cells (granulocytes) to boost the immune system and help fight the disease, with the goal of improving outcomes.
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
This Phase 2 trial studies using a cord blood transplant after finding it is risky enough that standard treatment may not be sufficient. It may help certain children and young adults with specific leukemia, lymphoma, and some non-cancer blood/immune or inherited disorders who do not have a well-matched donor available in time.
This Phase 2 study tests using donated cord blood to treat certain adult blood cancers that are at high risk of coming back. It may help strengthen the body’s ability to rebuild blood and fight the cancer after intensive treatment.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
Hear when a new AML (Acute Myelogenous Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.